Your browser doesn't support javascript.
loading
Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatment.
Guo, Yi-Gang; Zhang, Lu-Lu; Hu, Ping; Li, Zhang-Zhi; Zhang, Rui-Bo; Lv, Xi; Yi, Qiong; Zhan, Ling-Bo; Feng, Xue-Lian.
Afiliación
  • Guo YG; Department of Hematology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
  • Zhang LL; Department of Hematology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
  • Hu P; Department of Hematology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
  • Li ZZ; Department of Hematology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
  • Zhang RB; Children's Medical Center, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
  • Lv X; Department of Hematology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
  • Yi Q; Department of Hematology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
  • Zhan LB; Department of Hematology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
  • Feng XL; Children's Medical Center, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Hematology ; 29(1): 2304488, 2024 Dec.
Article en En | MEDLINE | ID: mdl-38299685
ABSTRACT

OBJECTIVE:

This study analyzed the relationship between bone marrow microvessel density (MVD) and the expression of four miRNAs with chronic myelogenous leukemia (CML) resistance after tyrosine kinase inhibitor (TKI) treatment.

METHODS:

234 CML patients were divided into resistance and non-resistance groups in terms of the results of the 5-year follow-up. Patients were divided into the Optimum response group and the Warning/Failure group based on TKI response. MVD was determined by immunohistochemistry, and the expression levels of four miRNAs (miR-106a, miR-155, miR-146a, and miR-340) in bone marrow biopsy specimens were examined by qPCR. We evaluated the association of MVD with four miRNAs and them predictive value for CML resistance after TKI treatment.

RESULTS:

The MVD and the levels of miR-106a, miR-155, and miR-146a were significantly higher while the miR-340 level was lower in the resistance group than the non-resistance group. Besides, MVD had a significant correlation with the levels of miR-340 and miR-155. According to the results of survival analysis, MVD as well as miR-340 and miR-155 levels were observably correlated with 5-year survival of patients without TKI resistance. The results of the ROC curve indicated that the MVD, miR-106a, miR-340, and miR-155 had good predictive accuracy for CML resistance after TKI treatment. As for the results of multivariate analysis, disease stage, risk level (high risk), high MVD, low miR-340 expression, and high miR-155 expression were all independent risk factors for CML resistance.

CONCLUSION:

MVD and the expression of miR-340 and miR-155 are closely associated with CML resistance after TKI treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / MicroARNs Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hematology Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / MicroARNs Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hematology Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido